Industry Roundtable | Advancing Clinical Trials for Neuroprotective Treatments Targeting Synucleinopathies

Industry Updates
Written By Kaleidoscope Management Group
 
 
 

Together, we’re making strides towards a brighter future in neurodegenerative disease research! 💡🔬🧠

We recently wrapped up our second Industry Roundtable at the Movement Disorders Society Congress in Philadelphia.

Our focus? Advancing clinical trials for neuroprotective treatments targeting synucleinopathies.

We had productive discussions with our industry partners about potential new research studies involving participants from the NAPS RBD registry, exploring outcome measures for clinical trials, and identifying emerging biomarkers.

 
Kaleidoscope Management Group
Previous

RBD Question of the Week❓💤💡 Is there a specific treatment to prevent neurodegeneration in those with RBD?
Next

Digital Biomarkers for Non-Motor Symptoms in Parkinson’s Disease